The influences of vitamin D and omega-3 co-supplementation on clinical, metabolic and genetic parameters in women with polycystic ovary syndrome
Journal of Affective Disorders, Vol 238, 1 Oct 2018, Pages 32-38, https://doi.org/10.1016/j.jad.2018.05.027
Mehri Jamiliana Mansooreh Samimib Naghmeh Mirhosseinic Faraneh Afshar Ebrahimib Esmat Aghadavodd Rezavan Talaeee Sadegh Jafarnejadd Shahrzad Hashemi Dizaji fZatollahAsemid
Starting to see Vitamin D combinations used for treatment in the Summer of 2018
This RCT used 50,000 IU vitamin D every 2 weeks plus 2000 mg/day Omega-3
- Search VitaminDWiki for PCOS 396 pages as of July 2018
- Fertility problem (PCOS) reduced by vitamin D: many studies
- PCOS (polycystic ovary syndrome) 4 times more likely if poor Vitamin D Receptor – Dec 2015
- Note Omega-3 increases the amount of Vitamin D getting to cells
- Vitamin D for depression and PCOS: killing two birds with one stone (title only - should be 60 birds) – July 2015 -Note: Omega-3 also decreases depression
Items in both categories Depression and Omega-3 are listed here:
- Psychotic disorders not treated by Omega-3 when patents take anti-depressants and get therapy – June 2018
- Happy Nurses Project gave Omega-3 for a year – reduced depression, insomnia, anxiety, etc – RCT July 2018
- Depression – is it reduced by Vitamin D and or Omega-3 – RCT 2019
- Benefits of Omega-3 beyond heart health - LEF Feb 2018
- Omega-3 improves gut bacteria, reduces inflammation and depression – Dec 2017
- Unipolar depression treated by Omega-3, Zinc, and probably Vitamin D – meta-analysis Oct 2017
- Omega-3 reduces many psychiatric disorders – 2 reviews 2016
- Omega-3 does not consistently treat depression if use small amounts for short time period – review Oct 2016
- How Omega-3 Fights Depression – LEF July 2016
- Depression due to inflammation reduced by Omega-3 (children and pregnant) – Nov 2015
- Depression treated somewhat by Omega-3 (St. John's Wort better) – RAND org reviews 2015
- Depression substantially decreased with Omega-3 – Sept 2015
- Omega-3 for just 3 months greatly reduced psychosis for 80 months – RCT Aug 2015
- Omega-3 prevents PTSD and some mood disorders - Aug 2015
- Omega-3, Vitamin D, and other nutrients decrease mental health problems – March 2015
Items in both categories Pregnancy and Omega-3 are listed here:
- More pregnancies and fewer abortions when Omega-3 was added (cows in this case) July 2018
- PCOS treated by a combination of Vitamin D and Omega-3 – RCT Oct 2018
- Omega-3 – fewer than 5 percent of adult women get the RDA – April 2018
- Supplementation while pregnant and psychotic – 20 percent Omega-3, 6 percent Vitamin D – June 2016
- Importance of Vitamin D and fish rarely mentioned during midwife-led prenatal booking visits – July 2017
- Pre-term birth rate of pregnant smokers cut in half if take Omega-3 – RCT May 2017
- Gestational diabetes treated by Vitamin D plus Omega-3 – RCT Feb 2017
- Asthma reduced 31 percent when Omega-3 taken during pregnancy – RCT Dec 2016
- Preterm births strongly related to Vitamin D, Vitamin D Receptor, Iodine, Omega-3, etc
- Typical pregnancy is now 39 weeks – Omega-3 and Vitamin D might restore it to full 40 weeks
- Omega-3 supplementation during pregnancy reduce early pre-term births (save 1500 USD per child) – Aug 2016
- Rancid Omega-3 increased the odds of newborn mortality by 13 times (rats) – July 2016
- Preterm birth extended by 2 weeks with Omega-3 – Meta-analysis Nov 2015
- Stillbirth rate typically 1 in 200, perhaps only 1 in 800 with Omega-3
- Omega-3 helps pregnancy in many ways: preterm 26 percent less likely etc – review July 2012
- Pregnancy and infants healthier with Omega-3 supplementation
- Vitamin D, DHA, Folic, Iodine benefits during pregnancy – July 2012
- This study has evaluated the effects of omega-3 plus vitamin D intake in PCOS women.
- Co-supplementation in PCOS women had beneficial effects on mental health.
- Co-supplementation in PCOS women improved metabolic profiles.
The aim of this study was to evaluate the effect of the co-administration of vitamin D and omega-3 fatty acid on clinical, metabolic and genetic parameters in women with polycystic ovary syndrome (PCOS).
This randomized, double-blinded, placebo-controlled clinical trial was conducted on 60 subjects, aged 18–40 years old with PCOS. Subjects were randomly allocated to take either 50,000 IU vitamin D every 2 weeks plus 2000 mg/day omega-3 fatty acid from fish oil (n = 30) or placebo (n = 30) for 12 weeks. Gene expression analysis of inflammatory cytokines was conducted on peripheral blood mononuclear cells (PBMCs) of PCOS women using RT-PCR method.
Vitamin D and omega -3 fatty acid co-supplementation significantly decreased serum total testosterone levels (−0.2 ± 0.5 vs. + 0.1 ± 0.4 ng/mL, P = 0.02) compared with the placebo. In addition, vitamin D and omega-3 fatty acid co-supplementation resulted in a
significant improvement in
- beck depression inventory (−1.4 ± 1.6 vs. −0.5 ± 0.6, P = 0.01),
- general health questionnaire scores (−4.5 ± 4.3 vs. −1.9 ± 2.3, P = 0.005) and
- depression anxiety and stress scale scores (−5.0 ± 5.1 vs. −2.3 ± 3.5, P = 0.01)
compared with the placebo.
Additionally, vitamin D and omega-3 fatty acid co-administration significantly decreased
- serum high-sensitivity C-reactive protein (hs-CRP) (−1.2 ± 1.9 vs. + 0.1 ± 0.7 mg/L, P = 0.001) and
- malondialdehyde (MDA) levels (−0.4 ± 0.4 vs. + 0.2 ± 0.6 µmol/L, P < 0.001), and
- plasma total antioxidant capacity (TAC) levels (+ 114.6 ± 122.2 vs. -2.4 ± 168.2 mmol/L, P = 0.003)
compared with the placebo. Results of RT-PCR demonstrated that vitamin D and omega-3 fatty acid co-supplementation significantly downregulated gene expression of interleukin-1 (IL-1) (P = 0.03), and upregulated vascular endothelial growth factor (VEGF) (P = 0.004) in PBMCs of subjects with PCOS, when compared with placebo.
Conclusions: Overall, the co-administration of vitamin D and omega-3 fatty acid for 12 weeks had beneficial effects on mental health parameters, serum total testosterone, hs-CRP, plasma TAC and MDA levels, and gene expression of IL-1 and VEGF among women with PCOS.